Melittin exerts antitumorigenic effects in human MM1.S multiple myeloma cells through the suppression of AKT/mTOR/S6K1/4E-BP1 signaling cascades

被引：2
作者：
Kim C. [1 ]
Kim D.S. [1 ]
Nam D. [1 ]
Kim S.-H. [1 ]
Shim B.S. [1 ]
Ahn K.S. [1 ]
机构：
[1] Department of Korean Pathology, College of Korean Medicine, Kyung Hee University, 1 Hoegidong Dongdaemungu, Seoul
来源：
Oriental Pharmacy and Experimental Medicine | 2015年 / 15卷 / 1期
关键词：
AKT/mTOR/S6K1/4E-BP1; Apoptosis; Melittin; MM1.S; Multiple myeloma;
D O I：
10.1007/s13596-014-0172-4
中图分类号：
学科分类号：
摘要：
Although melittin, a water-soluble 26-amino acid peptide derived from bee venom of Apis mellifera, is known to exert anti-proliferative effects on various tumor cell lines, very little is known about its potential molecular mechanism(s) of action. In the present study, we investigated the effects of melittin on the AKT/mTOR/S6K1/4E-BP1 activation, associated gene products, cellular proliferation, and apoptosis in several tumor cells. We found that melittin inhibited both constitutive phosphorylation of AKT and mTOR and exerted a significant time-dependent anti-proliferative effect on MM1.S cells as compared to other types of tumor cells. Indeed, melittin clearly suppressed the constitutive activation of AKT/mTOR/S6K1/4E-BP1 signaling cascades, which correlated with the induction of apoptosis. Melittin can cause broad-spectrum inhibition of AKT/mTOR/S6K1/4E-BP1 axes in multiple myeloma cells when compared with various pharmacological AKT/mTOR inhibitors. Aberrant AKT activation by pcDNA3-myr-HA-AKT1 plasmid could not prevent the observed suppressive effect of melittin on constitutive mTOR, S6K1, and 4E-BP1 activation and overexpression of Bcl-2 also attenuated melittin-mediated apoptosis in the cells. Our results clearly indicate that melittin can interfere with multiple signaling cascades involved in carcinogenesis and thereby used as a potential drug candidate for both the prevention and treatment of cancer. © 2014, Institute of Korean Medicine, Kyung Hee University and Springer Science+Business Media Dordrecht.
引用
收藏
页码：33 / 44
页数：11
相关论文
共 73 条
  • [1] Aggarwal B.B., Et al., Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution, Ann N Y Acad Sci, 1091, pp. 151-169, (2006)
  • [2] Ahn K.S., Sethi G., Aggarwal B.B., Nuclear factor-kappa B: from clone to clinic, Curr Mol Med, 7, pp. 619-637, (2007)
  • [3] Banko J.L., Poulin F., Hou L., DeMaria C.T., Sonenberg N., Klann E., The translation repressor 4E-BP2 is critical for eIF4F complex formation, synaptic plasticity, and memory in the hippocampus, J Neurosci, 25, pp. 9581-9590, (2005)
  • [4] Barlund M., Et al., Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis, J Natl Cancer Inst, 92, pp. 1252-1259, (2000)
  • [5] Bartlett J.M., Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions, Clin Breast Cancer, 10, pp. S86-S95, (2010)
  • [6] Berset C., Trachsel H., Altmann M., The TOR (target of rapamycin) signal transduction pathway regulates the stability of translation initiation factor eIF4G in the yeast Saccharomyces cerevisiae, Proc Natl Acad Sci U S A, 95, pp. 4264-4269, (1998)
  • [7] Bortner C.D., Oldenburg N.B., Cidlowski J.A., The role of DNA fragmentation in apoptosis, Trends Cell Biol, 5, pp. 21-26, (1995)
  • [8] Brunet A., Et al., Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor, Cell, 96, pp. 857-868, (1999)
  • [9] Campone M., Et al., Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours, Br J Cancer, 100, pp. 315-321, (2009)
  • [10] Chu S.T., Et al., Phospholipase A2-independent Ca2+ entry and subsequent apoptosis induced by melittin in human MG63 osteosarcoma cells, Life Sci, 80, pp. 364-369, (2007)
12345678